Showing 2211-2220 of 9226 results for "".
- ESCD 2026: New Data Show Ongoing Burden of Chronic Hand Eczemahttps://practicaldermatology.com/news/escd-2026-new-data-on-chronic-hand-eczema-burden-and-unmet-needs/2487581/LEO Pharma will present new data at the European Society of Contact Dermatitis (ESCD) Congress 2026 in Copenhagen highlighting the significant burden chronic hand eczema (CHE) continues to place on patients across different stages of life, according to a press release from the manufacturer. The p
- Emblation Partners With DermLite to Expand Access to Dermoscopy for Podiatristshttps://practicaldermatology.com/news/emblation-partners-with-dermlite-to-expand-access-to-dermoscopy-for-podiatrists/2487590/Emblation has announced a new collaboration with DermLite that will make the DermLite DL1 dermatoscope available through the Swift store, expanding access to dermoscopy tools for podiatrists using the company's Swift microwave therapy platform.
- Skin Cancer Champions Earns Two Digital Health Awards for Patient Education and Community Engagementhttps://practicaldermatology.com/news/skin-cancer-champions-earns-two-digital-health-awards-for-patient-education-and-community-engagement/2487580/Skin Cancer Champions, an online community dedicated to supporting patients and caregivers affected by non-melanoma skin cancers, has received two Bronze Awards in the Spring 2026 Digital Health Awards, presented by the Health Information Resource Center (HIRC). The awards recognize the or
- Takeda Reports Positive Phase 3 Results for Oral TYK2 Inhibitor Zasocitinibhttps://practicaldermatology.com/news/takeda-reports-positive-phase-3-results-for-oral-tyk2-inhibitor-zasocitinib/2487546/Takeda announced positive topline results from the Phase 3 LATITUDE Atlas (TAK-279-PsO-3004) trial, a head-to-head study evaluating the investigational oral tyrosine kinase 2 (TYK2) inhibitor zasocitinib (TAK-279) against deucravacitinib in adults with moderate-to-severe plaque psoriasis.
- AbbVie to Acquire Apogee Therapeutics in $10.9 Billion Immunology Dealhttps://practicaldermatology.com/news/abbvie-to-acquire-apogee-therapeutics-in-109-billion-immunology-deal/2487547/AbbVie announced a definitive agreement to acquire Apogee Therapeutics in an all-cash transaction valued at approximately $10.9 billion, a move the manufacturer said adds to its immunology pipeline and strengthens its presence in inflammatory diseases such as atopi
- Analysis Shows Long-Term Cost Impact of Psoriasis and Psoriatic Arthritishttps://practicaldermatology.com/news/analysis-highlights-long-term-cost-impact-of-psoriasis-and-psoriatic-arthritis/2487486/New research published in Dermatology and Therapy suggests the economic burden associated with psoriasis and psoriatic arthritis extends far beyond the diseases themselves and may reach hundreds of billions of dollars over a lifetime. Psoriatic Disease Comorbidities Drive Signifi
- Oral Nicotinamide Linked to Fewer Skin Cancers and Lower Treatment Costshttps://practicaldermatology.com/news/oral-nicotinamide-linked-to-fewer-skin-cancers-and-lower-treatment-costs/2487444/Oral nicotinamide may offer a cost-effective strategy for preventing keratinocyte carcinoma (KC) in patients at high risk for developing multiple skin cancers, according to a new economic evaluation conducted within the Veterans Health Administration (VHA) published in JAMA Dermatology.<
- FDA Approves EBGLYSS 8-Week Dosings in Atopic Dermatitishttps://practicaldermatology.com/news/fda-approves-ebglyss-8-week-dosings-in-atopic-dermatitis/2487424/The US Food and Drug Administration (FDA) has approved an every-8-week maintenance dosing regimen for EBGLYSS® (lebrikizumab-lbkz) in adults and adolescents aged 12 years and older weighing at least 40 kg with moderate-to-severe atopic dermatitis, according to an
- Genital Psoriasis Consensus Offers Age-Specific Roadmap for Clinical Carehttps://practicaldermatology.com/news/genital-psoriasis-consensus-offers-age-specific-roadmap-for-clinical-care/2487330/A new expert consensus manuscript in the American Journal of Clinical Dermatology offered recommendations aimed at improving the diagnosis and management of genital psoriasis, according to a press release from Arcutis. The publication represents the second manuscript, Arcutis said
- Skin Cancer Champions Announces Patient Advocacy Summithttps://practicaldermatology.com/news/skin-cancer-champions-announces-patient-advocacy-summit/2487322/The inaugural Patient Advocacy Summit, hosted by Skin Cancer Champions, will be held on October 30, 2026, at The Fairmont Copley Plaza in Boston, Massachusetts, the organization announced. “The Summit is an important milestone in our mission of providing support, advocacy, and amplifying t